2025-10-23T19:07:28+00:00 2024-12-31 135381590 BDO USA 200 PARK AVE 38TH FLOOR NEW YORK NY 10166 990 2024-01-01 134128413 GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC GLOB 2122277540 80 PINE STREET FL 20 NEW YORK NY 10005 MELVIN SPIGELMAN PRESIDENT/CEO 2025-10-24 true PAUL HAMMERSCHMIDT P01384178 2128858000 2025-10-24 2024 2025-03-06 01:10:19Z TB ALLIANCE MELVIN SPIGELMAN 80 PINE STREET FL 20 NEW YORK NY 10005 202456266 false X WWW.TBALLIANCE.ORG X 2000 DE TO ACCELERATE THE DISCOVERY & DEVELOPMENT OF NEW DRUGS TO FACILITATE THE CONTROL OF TUBERCULOSIS THROUGHOUT THE WORLD AND THE ACCESSIBILITY OF THESE DRUGS TO THE GLOBAL COMMUNITY. 12 11 50 11 0 49796816 52737212 0 0 8182816 9675203 2260854 1320142 60240486 63732557 278450 359938 0 0 17365566 17962003 0 1357698 37734563 43186842 55378579 61508783 4861907 2223774 197319541 204316428 25619991 28006599 171699550 176309829 TB ALLIANCE IS A NOT-FOR-PROFIT ORGANIZATION DEDICATED TO THE DISCOVERY, DEVELOPMENT AND DELIVERY OF BETTER, FASTER-ACTING AND AFFORDABLE TUBERCULOSIS DRUGS THAT ARE AVAILABLE TO THOSE WHO NEED THEM. false false 47923018 0 0 RESEARCH AND DEVELOPMENT - TB ALLIANCE IS A NOT-FOR-PROFIT PRODUCT DEVELOPMENT PARTNERSHIP (PDP), UNIQUELY POSITIONED TO LEVERAGE A GLOBAL NETWORK OF PUBLIC AND PRIVATE PARTNERS TO MOST EFFICIENTLY ADVANCE TB DRUG DEVELOPMENT. A PDP BUILDS PARTNERSHIPS BETWEEN THE PUBLIC, PRIVATE, ACADEMIC, AND PHILANTHROPIC SECTORS TO DRIVE THE DEVELOPMENT OF NEW PRODUCTS FOR UNDERSERVED MARKETS. PDPS RETAIN DIRECT MANAGEMENT OVERSIGHT OF THEIR PROJECTS, THOUGH MUCH OF THE LABORATORY AND CLINICAL WORK IS DONE THROUGH EXTERNAL RESEARCH FACILITIES AND CONTRACTORS. WE COMBINE THE RESEARCH AND DEVELOPMENT EXPERTISE OF OUR STAFF WITH THE SKILLS AND RESOURCES OF OUR PARTNERS TO HARNESS THE MOST PROMISING SCIENCE WHEREVER IT MAY EXIST AROUND THE WORLD. THIS MODEL MINIMIZES COSTS, INCLUDING OVERHEAD AND INVESTMENTS IN INFRASTRUCTURE, WHILE OPTIMIZING SCIENTIFIC CAPABILITY TO SPEED NEW TB DRUG DEVELOPMENT. OUR BUSINESS MODEL AND DIVERSE PARTNERSHIPS ALLOW TB ALLIANCE TO LEVERAGE ADDITIONAL PARTNER SERVICES FOR EVERY DOLLAR INVESTED IN ITS PROGRAMS. NC-009 - NC-009 IS A PAN-PHASE 2 CLINICAL TRIAL INCORPORATING ELEMENTS OF PHASE 2A, B, AND C TO EVALUATE THE SAFETY AND EFFICACY OF A COMBINATION OF A NEW EXPERIMENTAL COMPOUND, TBAJ-876, WITH PRETOMANID AND LINEZOLID, COMPONENTS OF TB ALLIANCE'S BPAL REGIMEN. THIS REGIMEN HAS THE POTENTIAL TO SHORTEN AND IMPROVE TREATMENT FOR BOTH DRUG-SENSITIVE AND DRUG-RESISTANT FORMS OF TB. RESULTS FROM PRECLINICAL AND PHASE 1 STUDIES WERE PRESENTED AT THE 2023 UNION CONFERENCE ON LUNG HEALTH AND SHOWED THAT THE NEW COMPOUND, TBAJ-876, WHEN COMPARED WITH BEDAQUILINE (A TB MEDICINE IN THE SAME DRUG CLASS), ELIMINATED TB BACTERIA FASTER AND HAD A POTENTIALLY SAFER PROFILE. NC-009 WILL TEST DIFFERENT DOSES OF TBAJ-876 IN COMBINATION WITH PRETOMANID AND LINEZOLID AGAINST THE CURRENT STANDARD OF CARE FOR DRUG-SENSITIVE TB - ISONIAZID, RIFAMPICIN, PYRAZINAMIDE, AND ETHEMBUTOL (HRZE). ANOTHER ARM OF THE TRIAL WILL ALSO TEST PRETOMANID AND LINEZOLID IN COMBINATION WITH BEDAQUILINE (BPAL), A REGIMEN NOW RECOMMENDED BY THE WORLD HEALTH ORGANIZATION TO TREAT SOME FORMS OF DR-TB, AGAINST DRUG-SENSISTIVE TB. THE STUDY ENROLLED APPRXIMATELY 300 PARTICIPANTS WITH DRUG-SENSITIVE TB AT 21 CLINICAL TRIAL SITES IN FIVE COUNTRIES: GEORGIA, PHILIPPINES, SOUTH AFRICA, TANZANIA, AND UGANDA. Q203 - TELACEBEC (Q203) IS A FIRST-IN-CLASS DRUG CANDIDATE AGAINST MYCOBACTERIUM TUBERCULOSIS INFECTION. Q203 TARGETS CYTOCHROME BC1 COMPLEX AND SHOWS POTENT ACTIVITY AGAINST MULTIDRUG-RESISTANT TUBERCULOSIS (MDR-TB). Q203 HAS ALSO BEEN FOUND EFFECTIVE AGAINST BURULI ULCER (MYCOBACTERIUM ULCERANS), A CHRONIC, NECROTIZING DISEASE THAT AFFECTS SKIN AND SOMETIMES BONE AND CAN LEAD TO PERMANENT DEFORMITY AND LONG-TERM DISABILITY, AND LEPROSY (MYCOBACTERIUM LEPRAE). IN 2023, TB ALLIANCE IN-LICENSED Q203 FROM QURIENT, A CLINICAL-STAGE BIOTECHNOLOGY COMPANY BASED IN SOUTH KOREA. IN JULY 2024, A PHASE 2 PROOF-OF-CONCEPT STUDY WAS INITIATED TO EXPLORE THE USE OF TELACEBEC (Q203) TO TREAT BURULI ULCER. IF SUCCESSFUL, A SINGLE DRUG COULD CUT TREATMENT DURATION BY MORE THAN HALF. IN PARTNERSHIP WITH TB ALLIANCE AND WITH SUPPORT FROM QURIENT CO. LTD, PROFESSOR DANIEL O'BRIEN - A PROMINENT CLINICIAN-RESEARCHER AND EXPERT IN BURULI ULCER - IS LEADING THE STUDY AT BARWON HEALTH AND THE ROYAL MELBOURNE HOSPITAL IN AUSTRALIA. THE TRIAL WILL ENROLL APPROXIMATELY 40 ADULT PATIENTS WITH BURULI ULCER WHO WILL RECEIVE 28 DAYS OF TELACEBEC (300MG) ONCE DAILY, FOLLOWED BY A YEAR OF OBSERVATION. PRELIMINARY RESULTS ARE EXPECTED IN 2025. TBAJ-587 - THIS NEXT-GENERATION DIARYLQUINOLINE PROJECT HAS SHOWN POTENTIAL TO MAINTAIN BEDAQUILINE'S IMPRESSIVE ANTI-TB ACTIVITIES WHILE RETAINING ADDITIONAL IMPROVED PROPERTIES. TBAJ-587 IS BEING STUDIED THROUGH THE INNOVATIVE HEALTH INITIATIVE'S ERA4TB PROJECT AND, IN 2024, TBAJ-587 COMPLETED A PHASE I TRIAL DEMONSTRATING POSITIVE RESULTS. RESULTS PUBLICATIONS ARE UNDERWAY. SUTEZOLID - SUTEZOLID IS A PROMISING CLINICAL-STAGE TB DRUG CANDIDATE FROM THE OXAZOLIDINONE CLASS. TB ALLIANCE HAS IMPLEMENTED AN OPEN DEVELOPMENT APPROACH TO ADVANCE THE PHASE 2 TB DRUG CANDIDATE, SUTEZOLID, WHICH COULD BE A COMPONENT OF A NEXT-GENERATION TB REGIMEN. TB ALLIANCE HAS MADE SUTEZOLID AVAILABLE FOR STUDY BY ALL RESEARCHERS WHO COMMIT TO MAKING THEIR RESULTS AVAILABLE TO THE BROADER TB RESEARCH COMMUNITY. THIS NOVEL APPROACH HAS CONTRIBUTED TO THREE CLINICAL TRIALS THAT BEGAN IN 2023. PEERLINC - IN 2024, TB ALLIANCE LAUNCHED A NEW PEER-TO-PEER LEARNING FOR INNOVATIVE CURES (PEERLINC) KNOWLEDGE HUB BASED IN MANILA, WITH FUNDING FROM THE AUSTRALIAN GOVERNMENT THROUGH THE PARTNERSHIPS FOR A HEALTHY REGION INITIATIVE. PEERLINC, OPERATING IN PARTNERSHIP BETWEEN TB ALLIANCE AND THE TROPICAL DISEASE FOUNDATION, INC. (TDF), AND IN CLOSE COLLABORATION WITH THE DEPARTMENT OF HEALTH (DOH), PHILIPPINES, WILL HELP COUNTRIES IMPLEMENT BEST PRACTICES IN THE TREATMENT OF DRUG-RESISTANT TUBERCULOSIS (DR-TB) TO HELP SPEED THE WORLDWIDE PROGRAMMATIC IMPLEMENTATION OF INNOVATIVE, MORE EFFECTIVE TREATMENTS FOR THE DISEASE, STARTING WITH THE WORLD HEALTH ORGANIZATION (WHO)-RECOMMENDED SIX-MONTH, ALL-ORAL BPAL/M REGIMENS, COMPOSED OF THE ANTIBIOTICS BEDAQUILINE (B), PRETOMANID (PA), AND LINEZOLID (L), WITH OR WITHOUT MOXIFLOXACIN (M). PEERLINC WILL PROVIDE PRACTICAL TRAINING AND TECHNICAL ASSISTANCE TO COUNTRIES TO SUPPORT THIS OBJECTIVE, VIA EXPERTS FROM THE PHILIPPINES AND THE DEPARTMENT OF HEALTH, INCLUDING LUNG CENTER OF THE PHILIPPINES AND THE NATIONAL TB REFERENCE LABORATORY (NTRL). THE PHILIPPINES HAS SUCCESSFULLY AND RAPIDLY DEPLOYED NEW TREATMENTS THROUGH PARTICIPATION IN TB ALLIANCE'S LEVERAGING INNOVATION FOR FASTER TB TREATMENT (LIFT-TB) INITIATIVE. IN 2024 ALONE, THE PEERLINC KNOWLEDGE HUB COMPLETED TRAININGS WITH LEADERS, EXPERTS, AND STAFF FROM NATIONAL TB PROGRAMS IN SEVEN COUNTRIES: PERU, DRC, NIGERIA, BRAZIL, CAMBODIA, TANZANIA, RWANDA. LIFT-TB (LEVERAGING INNOVATION FOR FASTER TREATMENT OF TB) - THIS ACCESS PROGRAM, LAUNCHED IN 2020, SEEKS TO INCREASE TREATMENT COMPLETION RATES FOR DRUG-RESISTANT TB THROUGH ADOPTION AND SCALE UP OF NEW REGIMENS, BEGINNING WITH BPAL. IT FOCUSES ON SEVEN HIGH-BURDEN SOUTHEAST AND CENTRAL ASIAN COUNTRIES THAT SHOULDER APPROXIMATELY 1 IN 5 OF THE GLOBAL TB CASES. AS OF 2024, MORE THAN 100 COUNTRIES HAVE PROCURED THE SIX-MONTH, ALL-ORAL BPAL REGIMEN TO TREAT MORE THAN 180,000 PEOPLE WITH DRUG-RESISTANT TB. FAST TRACK THE CURE - IN SUPPORT OF THE WORLD HEALTH ORGANIZATION'S CALL TO ACTION TO ACCELERATE ACCESS TO SHORTER DR-TB CURES FOR ALL, THE FAST TRACK THE CURE MOVEMENT BRINGS COMMUNITIES AROUND THE WORLD TOGETHER TO RAISE AWARENESS AND FACILITATE ACCESS TO NEW DR-TB TREATMENTS, WHILE RAMPING UP ADVOCACY TO CONVINCE WORLD LEADERS THAT SIX-MONTH DR-TB CURES MUST BE WIDELY ADOPTED AND AVAILABLE TO ALL WHO NEED THEM. FAST TRACK THE CURE IS ALSO COLLABORATING CLOSELY WITH STOP TB TO ENSURE STRATEGIC ALIGNMENT AND PARTNERSHIP AND WITH THE CHALLENGE FACILITY FOR CIVIL SOCIETY MOVEMENT, BY ALIGNING WITH THEIR COMMUNITY ENGAGEMENT, CAPACITY BUILDING, AND DEMAND CREATION PILLARS AND FOCUS. SLASH-TB - TB ALLIANCE AND THE SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE HAVE DEVELOPED SLASH-TB (SAVINGS FROM LEVERAGING & ADOPTING SHORTER & HIGHLY EGGECTIVE TB TREATMENTS), A MODEL TO ESTIMATE COST SAVINGS FOR HEALTH SERVICE SYSTEMS, PATIENTS, FAMILIES, AND/OR CAREGIVERS WHEN USING THE BPAL/M REGIMENS AS COMPARED TO STANDARD DRUG-RESISTANT TB TREATMENTS. 5642489 359938 0 PUBLIC AFFAIRS AND POLICY - TB ALLIANCE MAINTAINS CRITICAL ALLIANCES WITH PUBLIC AND PRIVATE ORGANIZATIONS TO RAISE AWARENESS ABOUT TUBERCULOSIS ("TB") AND ADVOCATE FOR PUBLIC AND PRIVATE INVOLVEMENT IN RESEARCH FOR THE PUBLIC GOOD. SPECIFICALLY, TB ALLIANCE NEGOTIATES TERMS THAT SUPPORT THE DEVELOPMENT AND ACCESS OF NEW AFFORDABLE ANTI-TB DRUGS EQUITABLY FOR THOSE AREAS MOST IN NEED WHILE ENCOURAGING THE PRIVATE SECTOR ON THE DEVELOPMENT OF THESE MEDICINES. TB ALLIANCE CONTINUES TO PURSUE AN EXPLICIT COMMITMENT TO OUR "AAA MANDATE" - THAT ALL NEW PRODUCTS WILL BE ADOPTED, AVAILABLE AND AFFORDABLE TO THOSE WITH TB. 852237 0 0 BUSINESS DEVELOPMENT - TB ALLIANCE NEGOTIATES, IMPLEMENTS AND MANAGES AGREEMENTS WITH PUBLIC AND PRIVATE ORGANIZATIONS WORLDWIDE AND DOES SO BY ADHERING TO SOUND BUSINESS PRACTICES WHILE ENSURING THE PUBLIC GOOD. SPECIFICALLY, TB ALLIANCE NEGOTIATES TERMS THAT SUPPORT THE DEVELOPMENT AND ACCESS OF NEW AFFORDABLE ANTI-TB DRUGS EQUITABLY TO THOSE AREAS MOST IN NEED WHILE ENCOURAGING THE PRIVATE SECTOR TO HELP DEVELOP NEW MEDICINES FOR TB INDICATIONS. 54417744 true true false false false false false false false false true true false true true true true false false true true true false false false false false false false true false false false false false false false false false false false false false false false false false false false false true 56 0 true 50 true false false false false false false false false false false false false X 12 11 false false false false false false false true true false false false true true true true true true true true false false NY X X ANGELA VANDERPLOEG 2122277540 80 PINE STREET 20TH FLOOR NEW YORK NY 10005 X ARIEL PABLOS-MENDEZ VICE-CHAIR 3.0 X X 0 0 0 DAVID NORTON CHAIR 3.0 X X 0 0 0 DR MELVIN SPIGELMAN PRESIDENT/CEO 45.0 X X 939703 0 113233 AKSHAY VAISHNAW DIRECTOR (AS OF 12/01/24) 3.0 X 0 0 0 ANN TAYLOR DIRECTOR (AS OF 09/01/24) 3.0 X 0 0 0 ERIC GOOSBY DIRECTOR 3.0 X 0 0 0 KIM SCHWARTZ DIRECTOR 3.0 X 0 0 0 MITCHELL WARREN DIRECTOR 3.0 X 0 0 0 RASHA HIBRI DIRECTOR 3.0 X 0 0 0 RATAN WATAL DIRECTOR 3.0 X 0 0 0 SRISHTI GUPTA DIRECTOR (AS OF 12/01/24) 3.0 X 0 0 0 SUNDAR KODIYALAM DIRECTOR 3.0 X 0 0 0 ANGELA VANDERPLOEG TREASURER/CFO 45.0 X 421854 0 104371 COLLEEN PERO SECRETARY/CAO 45.0 X 470044 0 71098 DR EUGENE SUN SR. VP, RESEARCH & DEVELOPMENT 45.0 X 580925 0 93318 DR NADER FOTOUHI SR. VP, CHIEF SCIENTIFIC OFFICER 45.0 X 565207 0 118405 MARIA BEUMONT VP, CHIEF MEDICAL OFFICER 45.0 X 497709 0 86293 PIETRO O TURILLI SR. VP, EXTERNAL AFFAIRS 45.0 X 369474 0 98009 KATHLEEN SCHOSTACK SR. VP, PROGRAM & ALLIANCE MANAGEMENT 45.0 X 432300 0 86259 RAJNEESH TANEJA VP, PHARMACEUTICAL PRODUCT DEVELOPMENT 45.0 X 370728 0 80940 ROBERT LORETTE SR. VP, BUSINESS DEVELOPMENT 45.0 X 448954 0 87286 SALAH FORAIDA SR. DIRECTOR, MEDICAL AFFAIRS 45.0 X 430090 0 52408 SANDEEP JUNEJA SR. VP, MARKET ACCESS 45.0 X 417509 0 103720 5944497 0 1095340 42 false true false PPD DEVELOPMENT LP 26361 NETWORK PLACE CHICAGO IL 60673 GLOBAL CRO 4305665 WUXI APPTEC (HONGKONG) LIMITED UNIT C 20/F NO 998 CANTON RD KOWLOON CH INTEGRATED R&D SERVICES 3501842 CERBA RESEARCH NV INDUSTRIEPARK ZWIJNAARDE 3 GHENT B Oost-Vlaanderen BE 9052 LAB COSTS 2778060 CLININVENT RESEARCH PVT LTD SURVEY NO 173/1 168 173/1AA GUMMADIDALA SANGAREDDY TELANGANA IN 50231 DRUG MANUFACTURING / TESTING 1999500 GLAXOSMITHKLINE INVESTIGACION 28760 TRES CANTOS MADRID SP EXTERNAL MINI PORTFOLIOS 1600000 75 35728256 17008956 52737212 0 0 0 0 0 6018797 0 0 6018797 387789 0 0 387789 0 0 142380115 138723709 3656406 0 3656406 0 0 3656406 0 MISCELLANEOUS INCOME 900099 932353 0 0 932353 0 0 0 0 932353 63732557 0 0 10995345 359938 359938 0 0 4529643 3106359 1077293 345991 10141255 7961031 1635853 544371 942313 744950 146067 51296 1606557 1260908 264453 81196 742235 564161 134862 43212 822060 722908 99152 0 142596 43000 99596 0 281815 0 281815 0 5644699 5161190 407709 75800 202203 17307 183058 1838 1082116 439587 605447 37082 1178518 858816 242283 77419 904955 607018 237153 60784 105276 92770 12506 0 263420 193961 51513 17946 215254 60704 154550 0 R&D PROJECT EXPENSES 32128355 32128355 0 DUES AND SUBSCRIPTIONS 215575 94781 100031 20763 0 0 0 0 61508783 54417744 5733341 1357698 5606240 0 138316993 34377400 1821719 6609856 1102554 1081288 0 0 0 0 1426170 1196922 6538126 5217651 1535911 1320475 31709868 80443114 0 64373689 0 15800086 14913684 197319541 204316428 8012001 8739913 1205080 2621045 0 0 16402910 16645641 25619991 28006599 X 171699550 176309829 171699550 176309829 197319541 204316428 X 2223774 2379897 6608 X false true true true true X 60247338 58183286 52646326 49796816 52737212 273610978 0 0 60247338 58183286 52646326 49796816 52737212 273610978 87396197 186214781 960126 77877 2686767 8339176 6406586 18470532 0 59988 392216 901316 1981851 932353 4267724 296349234 0 0.62836 0.63112 X Schedule A, Part II, Line 10 Other Income DESCRIPTION - , COLUMN A - 59988.0, COLUMN B - 392216.0, COLUMN C - 901316.0, COLUMN D - 1981851.0, COLUMN E - 932353.0, COLUMN F - 4267724.0; RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 4325574 3744076 581498 772908 720781 52127 1439644 752794 686850 1320475 Closely-held equity interests Financial derivatives INVESTMENTS IN LIMITED PARTNERSHIP 64373689 F 64373689 RIGHT-OF-USE - OPERATING LEASES 14853986 SECURITY DEPOSITS 59698 14913684 Federal Income Taxes OPERATING LEASE LIABILITIES 16645641 16645641 X 65830639 2379897 0 2379897 63450742 281815 0 281815 63732557 61226968 0 0 61226968 281815 0 281815 61508783 Schedule D, Part X, Line 2 FIN 48 (ASC 740) footnote TB ALLIANCE IS SUBJECT TO THE PROVISIONS OF THE FINANCIAL ACCOUNTING STANDARDS BOARD'S (FASB) ACCOUNTING STANDARDS CODIFICATION (ASC 740), INCOME TAXES (ASC 740), AS IT RELATES TO ACCOUNTING AND REPORTING FOR UNCERTAINTY IN INCOME TAXES. TB ALLIANCE DOES NOT BELIEVE IT HAS TAKEN ANY MATERIAL UNCERTAIN TAX POSITIONS AND, DUE TO ITS GENERAL NOT-FOR-PROFIT STATUS, MANAGEMENT BELIEVES ASC 740 HAS NOT HAD, AND IS NOT ANTICIPATED TO HAVE, A MATERIAL IMPACT ON TB ALLIANCE'S FINANCIAL STATEMENTS. true East Asia and the Pacific 0 0 Program Services ADMINISTRATIVE EXPENSES 4748 East Asia and the Pacific 0 11 Program Services CONSULTING SERVICES 590791 East Asia and the Pacific 0 0 Grantmaking 25762 East Asia and the Pacific 0 0 Program Services R&D RESEARCH 4012046 Europe (Including Iceland and Greenland) 0 0 Program Services ADMINISTRATIVE EXPENSES 118629 Europe (Including Iceland and Greenland) 0 15 Program Services CONSULTING SERVICES 1500861 Europe (Including Iceland and Greenland) 0 0 Grantmaking 5240 Europe (Including Iceland and Greenland) 0 0 Program Services R&D RESEARCH 6045806 Middle East and North Africa 0 0 Program Services ADMINISTRATIVE EXPENSES 21823 Middle East and North Africa 0 0 Program Services R&D RESEARCH 9349 North America (Canada & Mexico only) 0 2 Program Services CONSULTING SERVICES 52247 North America (Canada & Mexico only) 0 0 Program Services R&D RESEARCH 10310 Russia and Neighboring States 0 4 Program Services CONSULTING SERVICES 150600 Russia and Neighboring States 0 0 Grantmaking 13980 Russia and Neighboring States 0 0 Program Services R&D RESEARCH 636 South America 0 4 Program Services CONSULTING SERVICES 100470 South America 0 0 Program Services R&D RESEARCH 15026 South Asia 0 10 Program Services CONSULTING SERVICES 100487 South Asia 0 0 Program Services R&D RESEARCH 3292444 Sub-Saharan Africa 0 0 Program Services ADMINISTRATIVE EXPENSES 68187 Sub-Saharan Africa 1 6 Program Services SALARY & FRINGE BENEFITS EXPENSES 758369 Sub-Saharan Africa 0 8 Program Services CONSULTING SERVICES 45223 Sub-Saharan Africa 0 0 Program Services GRANTMAKING 314956 Sub-Saharan Africa 0 0 Program Services R&D RESEARCH 3235339 0 36 1 24 1 60 12663298 7830031 20493329 East Asia and the Pacific COMMUNITY ENENGAGEMENT 25762 WIRE Europe (Including Iceland and Greenland) COMMUNITY ENENGAGEMENT 5240 WIRE Russia and Neighboring States COMMUNITY ENENGAGEMENT 13980 WIRE Sub-Saharan Africa COMMUNITY ENENGAGEMENT 314956 WIRE 4 0 false false false false false false Schedule F, Part I, Line 2 Procedures for monitoring use of grant funds THE GRANTEE IS REQUIRED TO PROVIDE THE ORGANIZATION WITH AN ITEMIZED ACCOUNTING OF EXPENDITURES FOR THE PROJECT AND A REPORT ON THE PROGRESS OF THE PROJECT ON A SCHEDULE SPECIFIED IN THE AGREEMENT. THIS REQUIREMENT IS OUTLINED IN THE SIGNED AGREEMENT BETWEEN BOTH PARTIES. Schedule F, Part I, Line 3 Method used to account for expenditures on org's financial statements EAST ASIA AND THE PACIFIC-Accrual; EUROPE (INCLUDING ICELAND AND GREENLAND)-Accrual; MIDDLE EAST AND NORTH AFRICA-Accrual; NORTH AMERICA (CANADA & MEXICO ONLY)-Accrual; RUSSIA AND NEIGHBORING STATES-Accrual; SOUTH AMERICA-Accrual; SOUTH ASIA-Accrual; SUB-SAHARAN AFRICA-Accrual Schedule F, Part II, Line 1 Method used to account for expenditures on org's financial statements EAST ASIA AND THE PACIFIC-Accrual; EUROPE (INCLUDING ICELAND AND GREENLAND)-Accrual; RUSSIA AND NEIGHBORING STATES-Accrual; SUB-SAHARAN AFRICA-Accrual X X X X X false false false false false false false true false DR MELVIN SPIGELMAN PRESIDENT/CEO 664638 0 275065 0 0 0 69000 0 44233 0 1052936 0 0 0 COLLEEN PERO SECRETARY/CAO 375473 0 94571 0 0 0 46106 0 24992 0 541142 0 0 0 ANGELA VANDERPLOEG TREASURER/CFO 334028 0 87826 0 0 0 42395 0 61976 0 526225 0 0 0 DR NADER FOTOUHI SR. VP, CHIEF SCIENTIFIC OFFICER 448750 0 116457 0 0 0 56266 0 62139 0 683612 0 0 0 DR EUGENE SUN SR. VP, RESEARCH & DEVELOPMENT 461947 0 118978 0 0 0 54642 0 38676 0 674243 0 0 0 MARIA BEUMONT VP, CHIEF MEDICAL OFFICER 412534 0 85175 0 0 0 46000 0 40293 0 584002 0 0 0 PIETRO O TURILLI SR. VP, EXTERNAL AFFAIRS 293361 0 76113 0 0 0 36741 0 61268 0 467483 0 0 0 ROBERT LORETTE SR. VP, BUSINESS DEVELOPMENT 357997 0 90957 0 0 0 43907 0 43379 0 536240 0 0 0 SANDEEP JUNEJA SR. VP, MARKET ACCESS 330811 0 86698 0 0 0 41851 0 61869 0 521229 0 0 0 KATHLEEN SCHOSTACK SR. VP, PROGRAM & ALLIANCE MANAGEMENT 343593 0 88707 0 0 0 42820 0 43439 0 518559 0 0 0 SALAH FORAIDA SR. DIRECTOR, MEDICAL AFFAIRS 373254 0 56836 0 0 0 42937 0 9471 0 482498 0 0 0 RAJNEESH TANEJA VP, PHARMACEUTICAL PRODUCT DEVELOPMENT 306440 0 64288 0 0 0 36902 0 44038 0 451668 0 0 0 Schedule J, Part I, Line 7 Non-fixed payments VARIABLE COMPENSATION IS PAID TO STAFF MEMBERS BASED ON ANNUAL PERFORMANCE. REFER TO SCHEUDLE O RESPONSE TO FORM 990, PART VI, SECTION B, LINES 15 A and 15B FOR FURTHER DETAILS. Form 990, Part VI, Line 11b Review of form 990 by governing body FORM 990 WAS PREPARED BY A NATIONALLY RECOGNIZED ACCOUNTING FIRM IN CONJUNCTION WITH THE ORGANIZATION'S FINANCE DEPARTMENT. THE DRAFT OF FORM 990 WAS REVIEWED BY THE ORGANIZATION'S FINANCE DEPARTMENT AND SENIOR MANAGEMENT, AND THEN PROVIDED TO ALL MEMBERS OF THE BOARD OF DIRECTORS IN DRAFT VIA ELECTRONIC MAIL, WITH AN OPPORTUNITY FOR THEM TO COMMENT OR MAKE INQUIRY BEFORE IT WAS FILED WITH THE INTERNAL REVENUE SERVICE. Form 990, Part VI, Line 12c Conflict of interest policy THE ORGANIZATION'S CONFLICT OF INTEREST POLICY IS DISTRIBUTED TO OFFICERS AND DIRECTORS ANNUALLY ALONG WITH A QUESTIONNAIRE THAT IS COMPLETED BY ALL OFFICERS AND DIRECTORS IN WHICH THEY ARE ASKED TO DISCLOSE INFORMATION REGARDING ACTUAL OR POTENTIAL CONFLICTS OF INTEREST. THESE QUESTIONNAIRES ARE COLLECTED AND REVIEWED ANNUALLY TO ENSURE COMPLIANCE WITH THE CONFLICT OF INTEREST POLICY. THE POLICY ITSELF ALSO REQUIRES ANY DIRECTOR OR OFFICER TO PROMPTLY DISCLOSE ANY CONFLICT OF INTEREST. INTERESTED DIRECTORS AND OFFICERS ARE REQUIRED TO RECUSE THEMSELVES FROM ANY DECISION ON MATTERS IN WHICH THEY HAVE AN INTEREST, AND SUCH RECUSAL IS NOTED IN THE MINUTES. Form 990, Part VI, Line 15a Process to establish compensation of top management official THE COMPENSATION COMMITTEE, WHICH CONSISTS OF TWO INDEPENDENT BOARD MEMBERS, ANNUALLY REVIEWS THE CEO COMPENSATION IN CONJUNCTION WITH AN EVALUATION OF ORGANIZATIONAL PERFORMANCE. THE COMMITTEE RECOMMENDS ADJUSTMENTS IN COMPENSATION TO THE FULL BOARD FOR REVIEW AND APPROVAL, WITHIN THE CONTEXT OF AN AGREED UPON COMPETITIVE POSITION. THE COMPETITIVENESS OF COMPENSATION IS PERIODICALLY BENCHMARKED USING INDEPENDENT SALARY SURVEY DATA FROM THE NOT-FOR-PROFIT AND FOR-PROFIT INDUSTRY. THE COMPENSATION COMMITTEE DOCUMENTATION INCLUDES THE PERFORMANCE ASSESSMENT, COMPARABLE DATA AND THE SOURCE OF THIS DATA, AND THE RECOMMENDED ADJUSTMENTS. THE MINUTES OF THE FULL BOARD INCLUDE DOCUMENTATION OF THE APPROVED DECISIONS. THE MINUTES OF THE BOARD AND COMMITTEE ARE PREPARED BEFORE THE LATER OF THE NEXT MEETING OR 60 DAYS AFTER THE FINAL DECISION OF THE BOARD AND THE COMMITTEE. Form 990, Part VI, Line 15b Process to establish compensation of other employees THE COMPENSATION COMMITTEE, WHICH CONSISTS OF TWO INDEPENDENT BOARD MEMBERS, ANNUALLY REVIEWS OFFICERS COMPENSATION IN CONJUNCTION WITH AN EVALUATION OF ORGANIZATIONAL PERFORMANCE. THE COMMITTEE RECOMMENDS ADJUSTMENTS IN COMPENSATION TO THE FULL BOARD FOR REVIEW AND APPROVAL, WITHIN THE CONTEXT OF AN AGREED UPON COMPETITIVE POSITION. THE COMPETITIVENESS OF COMPENSATION IS PERIODICALLY BENCHMARKED USING INDEPENDENT SALARY SURVEY DATA FROM THE NOT-FOR-PROFIT AND FOR-PROFIT INDUSTRY. THE COMPENSATION COMMITTEE DOCUMENTATION INCLUDES THE PERFORMANCE ASSESSMENT, COMPARABLE DATA AND THE SOURCE OF THIS DATA, AND THE RECOMMENDED ADJUSTMENTS. THE MINUTES OF THE FULL BOARD INCLUDE DOCUMENTATION OF THE APPROVED DECISIONS. THE MINUTES OF THE BOARD AND COMMITTEE ARE PREPARED BEFORE THE LATER OF THE NEXT MEETING OR 60 DAYS AFTER THE FINAL DECISION OF THE BOARD AND THE COMMITTEE. Form 990, Part VI, Line 19 Required documents available to the public THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON REQUEST. Form 990, Part IX, Line 11g PROFESSIONAL SERVICES AND AGREEMENTS INCLUDE INDIVIDUAL CONSULTANTS WHO ARE CONTRIBUTING THEIR SPECIFIC EXPERTISE RELATED TO OUR CLINICAL TRIALS AND OTHER EARLY STAGE AND PRECLINICAL DISCOVERY WORK. EXPERTISE IN SUCH AREAS AS PHARMACOVIGILANCE, NON-GLP BIOANALYSIS, ANALYTICAL EVALUATION OF DRUG STABILITY AND PROGRAM MANAGEMENT ARE SOME OF THE SERVICES REQUIRED IN ORDER TO COMPLETE OUR SCIENTIFIC RESEARCH AND DEVELOPMENT. THESE CONSULTANTS ARE MANAGED BY OUR STAFF, WHO COORDINATE THE WORK NECESSARY TO BE COMPLETED AMONG ALL OUTSIDE PARTIES. Form 990, Part XI, Line 9 Other changes in net assets or fund balances FOREIGN TRANSLATION INCOME - 6608; Total - 6608;